Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study Comparing Rituximab-supplemented ABVD (R-ABVD) With ABVD Followed by Involved-field Radiotherapy (ABVD-RT) in Limited Stage (Stage I-IIA With no Areas of Bulk) Hodgkin's Lymphoma

NCT00992030 is registered in ClinicalTrials.gov with Fondazione Michelangelo as lead sponsor.

NCT NCT00992030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00992030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study Comparing Rituximab-supplemented ABVD (R-ABVD) With ABVD Followed by Involved-field Radiotherapy (ABVD-RT) in Limited Stage (Stage I-IIA With no Areas of Bulk) Hodgkin's Lymphoma
Lead sponsor
Fondazione Michelangelo
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2009
Completion date
March 31, 2019
Enrollment
112 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma